J Interferon Cytokine Res 2003 Mar;23(3):127-33
Kilinc M, Saatci-Cekirge I, Karabudak R.
Neurology Department, Baskent University Hospital, Ankara, Turkey.
In this controlled study, we investigated the serum and cerebrospinal fluid (CSF) levels of soluble intercellular adhesion molecule-1 (sICAM-1) in relapsing-remitting multiple sclerosis (RRMS) patients and changes in the levels of this adhesion molecule during interferon-beta1b (IFN-beta1b) treatment.
We also investigated the changes in the levels of sICAM-1 in correlation with disease activity and with findings on magnetic resonance images (MRI).
The study included 24 patients (16 females and 8 males) who were confirmed to have RRMS based on the criteria of Poser et al.
Sixteen of the patients received IFN-beta1b (Betaseron((R)), Berlex Laboratories, Schering AG Germany, Berlin) treatment, and 8 did not receive this therapy.
The levels of sICAM-1 in the MS patients' serum and CSF were significantly higher than levels in individuals with noninflammatory neurologic disease (p = 0.0081 and p = 0.0001, respectively).
In the first 3 months of the study, MS patients treated with IFN-beta1b showed a significant rise in sICAM-1 levels (p = 0.0023), whereas their untreated counterparts showed no significant change.
Neither of the groups showed a significant correlation between sICAM-1 level and disease activity demonstrated by MRI or between sICAM-1 level and clinical disease activity.
The findings suggest that IFN-beta1b treatment may have a short-term upregulating effect on sICAM-1.